MDNAF
Medicenna Therapeutics Corp.
Price Chart
Latest Quote
$0.31
-0.01 (-1.59%)
Current Price
| Previous Close | $0.32 |
| Open | $0.30 |
| Day High | $0.30 |
| Day Low | $0.30 |
| Volume | 5,500 |
Stock Information
Note: Financial values converted from CAD to USD
| Shares Outstanding | 92.30M |
| Total Debt | $74K |
| Cash Equivalents | $4.07M |
| Net Income | $-13.29M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $28.61M |
| EPS (TTM) | $-0.16 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $23.03M |
| Income | $-13.29M |
| Book/sh | $0.01 |
| Cash/sh | $0.06 |
| Employees | 15 |
Financial Ratios
| Quick Ratio | 1.11 |
| Current Ratio | 1.25 |
| Debt/Eq | 6.22 |
Returns & Margins
| ROA | -90.10% |
| ROE | -227.57% |
Ownership
| Insider Ownership | 18.82% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.82 |
| P/B | 24.19 |
Analyst Data
| Recommendation | none |
| Target Price | $4.25 |
Technical Indicators
| SMA20 | $0.31 |
| SMA50 | $0.31 |
| SMA200 | $0.40 |
| RSI | 52.11 |
| ATR | 0.0250 |
| Shares Float | 74.34M |
| Short Float | 0.70% |
| Short Ratio | 0.77 |
| Volatility | 2.21 |
| Rel Volume | 0.67 |
Performance History
| Week | +0.00% |
| Month | +9.15% |
| Quarter | +13.97% |
| 6 Months | -32.46% |
| YTD | -57.30% |
| Year | -70.22% |
| 3 Years | +57.36% |
| 5 Years | -86.04% |
| 10 Years | -86.16% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-11-03 | $0.31 | 19,500 |
| 2026-11-02 | $0.31 | 1,100 |
| 2026-10-30 | $0.31 | 18,300 |
| 2026-10-29 | $0.35 | 4,500 |
| 2026-10-28 | $0.33 | 48,000 |
| 2026-10-27 | $0.31 | 30,400 |
| 2026-10-26 | $0.30 | 13,600 |
| 2026-10-23 | $0.31 | 28,700 |
| 2026-10-22 | $0.28 | 30,300 |
| 2026-10-21 | $0.29 | 90,700 |
| 2026-10-20 | $0.28 | 85,600 |
| 2026-10-19 | $0.28 | 42,100 |
| 2026-10-16 | $0.30 | 9,000 |
| 2026-10-15 | $0.31 | 3,100 |
| 2026-10-14 | $0.30 | 29,700 |
| 2026-10-13 | $0.31 | 72,400 |
| 2026-10-12 | $0.31 | 20,700 |
| 2026-10-09 | $0.32 | 23,000 |
| 2026-10-08 | $0.31 | 0 |
| 2026-10-07 | $0.31 | 10,200 |
| 2026-10-06 | $0.31 | 512,300 |
| 2026-10-05 | $0.28 | 40,700 |
About Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
đ° Latest News
No news articles available at the moment. Check back later for updates on MDNAF.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $20,406,000 | $18,674,000 | $16,303,000 | $22,473,000 |
| Other Income Expense | $7,251,000 | $-7,990,000 | $5,341,000 | $-173,000 |
| Net Non Operating Interest Income Expense | $1,350,000 | $1,198,000 | $914,000 | $69,000 |
| Operating Expense | $20,406,000 | $18,674,000 | $16,303,000 | $22,473,000 |
| General And Administrative Expense | $5,907,000 | $7,869,000 | $6,994,000 | $7,720,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-11,805,000 | $-25,466,000 | $-10,048,000 | $-22,577,000 |
| Net Interest Income | $1,350,000 | $1,198,000 | $914,000 | $69,000 |
| Interest Income | $1,350,000 | $1,198,000 | $914,000 | $69,000 |
| Normalized Income | $-19,056,000 | $-17,476,000 | $-15,389,000 | $-22,404,000 |
| Net Income From Continuing And Discontinued Operation | $-11,805,000 | $-25,466,000 | $-10,048,000 | $-22,577,000 |
| Net Income Common Stockholders | $-11,805,000 | $-25,466,000 | $-10,048,000 | $-22,577,000 |
| Net Income | $-11,805,000 | $-25,466,000 | $-10,048,000 | $-22,577,000 |
| Net Income Including Noncontrolling Interests | $-11,805,000 | $-25,466,000 | $-10,048,000 | $-22,577,000 |
| Net Income Continuous Operations | $-11,805,000 | $-25,466,000 | $-10,048,000 | $-22,577,000 |
| Pretax Income | $-11,805,000 | $-25,466,000 | $-10,048,000 | $-22,577,000 |
| Interest Income Non Operating | $1,350,000 | $1,198,000 | $914,000 | $69,000 |
| Operating Income | $-20,406,000 | $-18,674,000 | $-16,303,000 | $-22,473,000 |
| Depreciation Amortization Depletion Income Statement | $55,000 | $5,000 | $5,000 | $37,000 |
| Depreciation And Amortization In Income Statement | $55,000 | $5,000 | $5,000 | $37,000 |
| Depreciation Income Statement | $55,000 | $5,000 | $5,000 | $37,000 |
| Per Share | ||||
| Diluted EPS | $-0.15 | $-0.37 | $-0.16 | $-0.42 |
| Basic EPS | $-0.15 | $-0.37 | $-0.16 | $-0.42 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-27,602,000 | $-10,679,000 | $-21,639,000 | $-22,262,000 |
| Total Unusual Items | $7,251,000 | $-7,990,000 | $5,341,000 | $-173,000 |
| Total Unusual Items Excluding Goodwill | $7,251,000 | $-7,990,000 | $5,341,000 | $-173,000 |
| Reconciled Depreciation | $53,000 | $4,000 | $4,000 | $38,000 |
| EBITDA (Bullshit earnings) | $-20,351,000 | $-18,669,000 | $-16,298,000 | $-22,435,000 |
| EBIT | $-20,406,000 | $-18,674,000 | $-16,303,000 | $-22,473,000 |
| Diluted Average Shares | $76,671,175 | $69,637,469 | $64,736,493 | $54,286,671 |
| Basic Average Shares | $76,671,175 | $69,637,469 | $64,736,493 | $54,286,671 |
| Diluted NI Availto Com Stockholders | $-11,805,000 | $-25,466,000 | $-10,048,000 | $-22,577,000 |
| Gain On Sale Of Security | $7,251,000 | $-7,990,000 | $5,341,000 | $-173,000 |
| Research And Development | $14,444,000 | $10,800,000 | $9,304,000 | $14,716,000 |
| Selling General And Administration | $5,907,000 | $7,869,000 | $6,994,000 | $7,720,000 |
| Other Gand A | $2,878,000 | $5,522,000 | $5,185,000 | $5,808,000 |
| Salaries And Wages | $3,029,000 | $2,347,000 | $1,809,000 | $1,912,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $19,043,000 | $5,134,000 | $29,425,000 | $20,770,000 |
| Total Assets | $28,382,000 | $19,134,000 | $36,446,000 | $23,456,000 |
| Total Non Current Assets | $211,000 | $57,000 | $61,000 | $65,000 |
| Goodwill And Other Intangible Assets | $52,000 | $57,000 | $61,000 | $65,000 |
| Current Assets | $28,171,000 | $19,077,000 | $36,385,000 | $23,391,000 |
| Prepaid Assets | $639,000 | $931,000 | $1,934,000 | $1,548,000 |
| Receivables | $2,695,000 | $1,164,000 | $855,000 | $1,308,000 |
| Taxes Receivable | $2,695,000 | $1,164,000 | $855,000 | $1,308,000 |
| Cash Cash Equivalents And Short Term Investments | $24,837,000 | $16,982,000 | $33,596,000 | $20,535,000 |
| Cash And Cash Equivalents | $24,837,000 | $16,982,000 | $33,596,000 | $20,535,000 |
| Cash Equivalents | $23,559,000 | $11,200,000 | $32,800,000 | $5,000,000 |
| Cash Financial | $1,278,000 | $5,782,000 | $796,000 | $15,535,000 |
| Other Receivables | - | - | - | - |
| Debt | ||||
| Total Debt | $168,000 | $0 | - | $0 |
| Long Term Debt And Capital Lease Obligation | $119,000 | $0 | - | - |
| Current Debt And Capital Lease Obligation | $49,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $9,287,000 | $13,943,000 | $6,960,000 | $2,621,000 |
| Total Non Current Liabilities Net Minority Interest | $4,852,000 | $11,080,000 | $3,160,000 | $0 |
| Derivative Product Liabilities | $4,733,000 | $11,080,000 | $3,160,000 | $0 |
| Current Liabilities | $4,435,000 | $2,863,000 | $3,800,000 | $2,621,000 |
| Payables And Accrued Expenses | $4,386,000 | $2,863,000 | $3,800,000 | $2,621,000 |
| Payables | $2,701,000 | $2,070,000 | $1,617,000 | $1,672,000 |
| Accounts Payable | $2,701,000 | $2,070,000 | $1,617,000 | $1,672,000 |
| Equity | ||||
| Common Stock Equity | $19,095,000 | $5,191,000 | $29,486,000 | $20,835,000 |
| Total Equity Gross Minority Interest | $19,095,000 | $5,191,000 | $29,486,000 | $20,835,000 |
| Stockholders Equity | $19,095,000 | $5,191,000 | $29,486,000 | $20,835,000 |
| Other Equity Interest | $9,831,000 | - | - | - |
| Gains Losses Not Affecting Retained Earnings | $3,000 | $19,000 | $57,000 | $171,000 |
| Other Equity Adjustments | $3,000 | $19,000 | $57,000 | $171,000 |
| Retained Earnings | $-118,252,000 | $-106,447,000 | $-80,981,000 | $-70,933,000 |
| Other | ||||
| Ordinary Shares Number | $78,215,735 | $69,637,469 | $69,637,469 | $55,647,479 |
| Share Issued | $78,215,735 | $69,637,469 | $69,637,469 | $55,647,479 |
| Tangible Book Value | $19,043,000 | $5,134,000 | $29,425,000 | $20,770,000 |
| Invested Capital | $19,095,000 | $5,191,000 | $29,486,000 | $20,835,000 |
| Working Capital | $23,736,000 | $16,214,000 | $32,585,000 | $20,770,000 |
| Capital Lease Obligations | $168,000 | $0 | - | $0 |
| Total Capitalization | $19,095,000 | $5,191,000 | $29,486,000 | $20,835,000 |
| Additional Paid In Capital | $11,216,000 | $10,695,000 | $9,486,000 | $7,926,000 |
| Capital Stock | $116,297,000 | $100,924,000 | $100,924,000 | $83,671,000 |
| Common Stock | $116,297,000 | $100,924,000 | $100,924,000 | $83,671,000 |
| Long Term Capital Lease Obligation | $119,000 | $0 | - | - |
| Current Capital Lease Obligation | $49,000 | $0 | - | $0 |
| Current Accrued Expenses | $1,685,000 | $793,000 | $2,183,000 | $949,000 |
| Net PPE | $159,000 | $0 | - | $0 |
| Gross PPE | $159,000 | $0 | - | $0 |
| Other Properties | $18,000 | - | - | - |
| Buildings And Improvements | $141,000 | $0 | - | - |
| Properties | $0 | $0 | - | - |
| Other Short Term Investments | - | - | - | $0 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-16,525,000 | $-16,260,000 | $-12,657,000 | $-23,584,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-16,492,000 | $-16,260,000 | $-12,657,000 | $-23,584,000 |
| Cash Flow From Continuing Operating Activities | $-16,492,000 | $-16,260,000 | $-12,657,000 | $-23,584,000 |
| Operating Gains Losses | $-7,251,000 | $8,236,000 | $-5,230,000 | $121,000 |
| Investing Activities | ||||
| Capital Expenditure | $-33,000 | - | - | - |
| Investing Cash Flow | $-33,000 | $0 | $0 | $10,050,000 |
| Cash Flow From Continuing Investing Activities | $-33,000 | $0 | $0 | $10,050,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $19,714,000 | $0 | $24,760,000 | $3,509,000 |
| Financing Cash Flow | $23,492,000 | $0 | $24,760,000 | $3,878,000 |
| Cash Flow From Continuing Financing Activities | $23,492,000 | $0 | $24,760,000 | $3,878,000 |
| Net Common Stock Issuance | $19,714,000 | $0 | $24,760,000 | $3,509,000 |
| Common Stock Issuance | $19,714,000 | $0 | $24,760,000 | $3,509,000 |
| Other | ||||
| Repayment Of Debt | $-19,000 | $0 | $0 | $-37,000 |
| End Cash Position | $24,837,000 | $16,982,000 | $33,596,000 | $20,535,000 |
| Beginning Cash Position | $16,982,000 | $33,596,000 | $20,535,000 | $30,375,000 |
| Effect Of Exchange Rate Changes | $888,000 | $-354,000 | $958,000 | $-184,000 |
| Changes In Cash | $6,967,000 | $-16,260,000 | $12,103,000 | $-9,656,000 |
| Proceeds From Stock Option Exercised | $3,797,000 | $0 | $0 | $406,000 |
| Net Issuance Payments Of Debt | $-19,000 | $0 | $0 | $-37,000 |
| Net Long Term Debt Issuance | $-19,000 | $0 | $0 | $-37,000 |
| Long Term Debt Payments | $-19,000 | $0 | $0 | $-37,000 |
| Net PPE Purchase And Sale | $-33,000 | $0 | - | - |
| Purchase Of PPE | $-33,000 | $0 | - | - |
| Change In Working Capital | $1,314,000 | $741,000 | $2,410,000 | $-1,844,000 |
| Change In Payables And Accrued Expense | $1,523,000 | $-937,000 | $1,179,000 | $-1,452,000 |
| Change In Receivables | $-209,000 | $1,678,000 | $1,231,000 | $-392,000 |
| Other Non Cash Items | $-1,017,000 | $-984,000 | $-1,164,000 | $-737,000 |
| Stock Based Compensation | $2,214,000 | $1,209,000 | $1,371,000 | $1,415,000 |
| Depreciation Amortization Depletion | $53,000 | $4,000 | $4,000 | $38,000 |
| Depreciation And Amortization | $53,000 | $4,000 | $4,000 | $38,000 |
| Depreciation | $53,000 | $4,000 | $4,000 | $38,000 |
| Gain Loss On Investment Securities | $-6,347,000 | $7,920,000 | $-4,158,000 | - |
| Net Foreign Currency Exchange Gain Loss | $-904,000 | $316,000 | $-1,072,000 | $121,000 |
| Net Income From Continuing Operations | $-11,805,000 | $-25,466,000 | $-10,048,000 | $-22,577,000 |
| Net Investment Purchase And Sale | - | - | $0 | $10,050,000 |
| Sale Of Investment | - | - | $0 | $20,050,000 |
| Purchase Of Investment | - | - | $0 | $-10,000,000 |
Fetched: 2026-02-02